Unichem Laboratories Limited

Unichem Laboratories Limited (UNICHEMLAB) is a micro-cap Healthcare company valued at ₹3,593 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Unichem Laboratories Limited last traded at ₹511.15, modestly down 1.93% on the day.

Recent developments

On 2026-06-30, the company reported a net profit of ₹41 crore for the latest quarter, marking a turnaround from a net loss of ₹10 crore in the same period a year earlier. Promoter holding remained at 70.22% as of 2026-06-30, while foreign institutional holding decreased by 0.10 percentage points and domestic institutional holding fell by 0.17 percentage points.

Financial performance

The company's business has improved significantly, with annual net profit rising 83.2% to ₹253 crore, driven by a sharp increase in net profit margin to 11.5% from 6.5% a year earlier. The latest quarter saw a turnaround from a net loss of ₹10 crore to a profit of ₹41 crore, while revenue grew 20.0% year-on-year to ₹633 crore.

Valuation multiples

The stock trades at 12.3 times earnings, a discount to the Healthcare median of 32.0, 1.38 times book value. It yields 0.8%.

Things to watch

The company's return on equity is 0.0%, indicating no return to shareholders from retained earnings. The stock is 22.1% below its 52-week high, and the latest quarter's net profit swung from a loss to a profit, suggesting volatility in recent performance. Debt to equity is low at 0.18, but the return on capital employed is 10.1%, which is below the return on equity.

Where it stands

The company has shown strong profit growth, with net profit rising 83.2% annually and turning around to a profit in the latest quarter. The stock is 22.1% below its 52-week high, and the return on equity remains at 0.0%, highlighting the need for further capital efficiency. The latest quarter's net profit change marks a significant shift from a loss to a profit, indicating a positive trend in recent performance.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.